Kimelman & Baird LLC Trims Holdings in STERIS plc (NYSE:STE)

Kimelman & Baird LLC reduced its position in shares of STERIS plc (NYSE:STE - Free Report) by 10.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 25,673 shares of the medical equipment provider's stock after selling 3,026 shares during the quarter. Kimelman & Baird LLC's holdings in STERIS were worth $5,277,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Avalon Trust Co bought a new position in shares of STERIS during the 4th quarter valued at approximately $30,000. Human Investing LLC bought a new position in shares of STERIS during the 4th quarter valued at approximately $31,000. Anfield Capital Management LLC grew its stake in shares of STERIS by 100.0% during the 4th quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider's stock valued at $37,000 after acquiring an additional 91 shares during the period. Central Pacific Bank Trust Division grew its stake in shares of STERIS by 65.5% during the 4th quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider's stock valued at $39,000 after acquiring an additional 76 shares during the period. Finally, Manchester Capital Management LLC grew its stake in shares of STERIS by 182.7% during the 4th quarter. Manchester Capital Management LLC now owns 212 shares of the medical equipment provider's stock valued at $44,000 after acquiring an additional 137 shares during the period. 94.69% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on STE. Piper Sandler boosted their price target on STERIS from $260.00 to $265.00 and gave the stock an "overweight" rating in a report on Monday, February 3rd. Stephens reaffirmed an "overweight" rating and issued a $240.00 price objective on shares of STERIS in a research report on Thursday, February 6th. Finally, JMP Securities reissued a "market outperform" rating and set a $265.00 price target on shares of STERIS in a research report on Thursday, February 6th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $258.75.

Remove Ads

STERIS Stock Up 0.2 %

Shares of NYSE STE traded up $0.48 during mid-day trading on Tuesday, reaching $228.29. 454,011 shares of the company were exchanged, compared to its average volume of 500,986. The company has a quick ratio of 1.40, a current ratio of 2.13 and a debt-to-equity ratio of 0.32. The stock has a market cap of $22.43 billion, a price-to-earnings ratio of 48.47 and a beta of 0.92. STERIS plc has a 1 year low of $197.82 and a 1 year high of $248.24. The firm has a 50-day moving average of $219.65 and a 200 day moving average of $222.31.

STERIS (NYSE:STE - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share for the quarter, missing analysts' consensus estimates of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. On average, research analysts expect that STERIS plc will post 9.08 earnings per share for the current year.

STERIS Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 21st. Stockholders of record on Thursday, February 20th will be paid a $0.57 dividend. This represents a $2.28 annualized dividend and a dividend yield of 1.00%. The ex-dividend date is Thursday, February 20th. STERIS's payout ratio is 48.41%.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.